This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out
ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysExplore ContentEventsMaterialsVideosContact

Menu

Close

HomeAboutAboutHow TRUMENBA WorksTru Patient StoriesAre Your Patients Protected?CDC RecommendationsDosingEfficacy & SafetyEfficacy & SafetySafety Profile and TolerabilityImmunogenicity & PersistenceSupport & OrderSupport & OrderEventsMaterialsVideosWelcome to TruSupportOrdering & InventoryCoverage & ReimbursementPatient Adherence
Prescribing InformationIndicationMedical Information
Coverage & ReimbursementACIP-Recommended MenB Vaccines Are Covered by Most Insurance Plans1,2

ACIP=Advisory Committee on Immunization Practices.

Scroll left to view table
Coding for TRUMENBA3
CDC immunization schedule highlights vaccines for 16 year olds
Type Code
CPT®* 90621
Pediatric CPT Codes 90460: Administration of a vaccine with counseling; first vaccine/component
90471: Administration of a vaccine without counseling
NDC 0005-0100-10 TRUMENBA single dose
(10 per package)
0005-0100-05 TRUMENBA single dose
(5 per package)
ReferencesCPT is a registered trademark of the American Medical Association.
Scroll left to view table
Diagnosis coding for TRUMENBA4
ICD-10 Diagnosis Code Description
Z23 Encounter for Immunization
Note: Additional ICD-10 codes may be needed depending on the type of patient visit and for immunizations administered during inpatient care.
Pfizer reserves the right to limit orders by packaging within any given month based on an individual’s purchase history. If an order above the allowance is received, Pfizer reserves the right to cancel the excess amount.ACIP=Advisory Committee on Immunization Practices; ICD-10=International Classification of Diseases, 10th Revision; NDC=National Drug Code.  Reach the Pfizer Vaccines Reimbursement Support Services at:
Telephone: 1-866-744-3198
Fax: 1-866-744-3303
Monday through Friday
8:00 am-8:00 pm ETTitle
Contact your Pfizer Sales Representative or call a Vaccine Specialist at 1-800-666-7248.
References:1. Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices. Recommended child and adolescent immunization schedule for ages 18 years or younger, United States, 2023. Centers for Disease Control and Prevention website. Updated September 27, 2023. Accessed November 6, 2023. https://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf. 2. Data on file. Pfizer Inc., New York, New York. 
3. TRUMENBA [package insert]. Philadelphia, PA: Pfizer Inc.; 2021. 4. Centers for Medicare and Medicaid Services (CMS). ICD-10-CM official guidelines for coding and reporting: FY 2021. CMS website. https://www.cms.gov/files/document/2021-coding-guidelines-updated-12162020.pdf. Accessed December 2, 2021.Support & Order Ordering & inventory with TruSupport

Provides multiple convenient options for ordering TRUMENBA​​​​​​

View the options
Loading Coverage & reimbursement with TruSupport

Streamlines the processes of confirming your patient's coverage for TRUMENBA

Learn how Pfizer streamlines
Loading

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2024 Pfizer Inc. All rights reserved.

PP-TRU-USA-3171
You are now leaving Pfizer

You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.

PP-MCL-USA-0367

INDICATION
  • Trumenba is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age
Important Safety Information
  • Severe allergic reaction (eg, anaphylaxis) to any component of Trumenba is a contraindication
  • Some individuals with altered immunocompetence may have reduced immune responses to Trumenba
  • Persons with certain complement deficiencies and persons receiving treatment that inhibits terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by Neisseria meningitidis serogroup B even if they develop antibodies following vaccination with Trumenba
  • Vaccination with Trumenba may not protect all vaccine recipients against N meningitidis serogroup B infections
  • Syncope (fainting) can occur in association with administration of injectable vaccines, including Trumenba. Procedures should be in place to avoid injury from fainting
  • In clinical studies, the most common solicited adverse reactions in adolescents and young adults were pain at injection site (≥85%), fatigue (≥60%), headache (≥55%), and muscle pain (≥35%) 
  • Data are not available on the safety and effectiveness of using Trumenba and other meningococcal group B vaccines interchangeably to complete the vaccination series
  • Safety and effectiveness have not been established in pregnant women
Indication
  • Trumenba is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age
Please see full Prescribing Information.